Media & Press2019-09-17T16:08:49-04:00

    Bexion Pharmaceuticals, Inc. to Present at the 2022 European Association of Neuro-Oncology (EANO 2022)

    September 14, 2022|

    FOR IMMEDIATE RELEASE [Covington, KY--- 14 September 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria ... Read More

      Bexion Pharmaceuticals, Inc. to Present at the 2022 International Symposium on Pediatric Neuro-Oncology (IPSNO) Annual Conference

      June 13, 2022|

      FOR IMMEDIATE RELEASE [Covington, KY---June 13, 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company, announced today that two abstracts submitted for an in-person session at the IPSNO annual meeting to be held in Hamburg, Germany, June 12-15, 2022 has been chosen for poster presentation. ISPNO is the largest international scientific meeting of multidisciplinary professionals ... Read More

        Bexion Pharmaceuticals, Inc. Welcomes New Chief Financial Officer

        June 2, 2022|

        Seasoned BIO/Pharma Executive adds finance, strategic capital access and public market readiness to the management team FOR IMMEDIATE RELEASE [Covington, KY---June 2, 2022l] Bexion Pharmaceuticals, Inc., a mid-stage biopharmaceutical company developing innovative therapies for cancers and chemotherapy induced peripheral neuropathy (CIPN), announced today that Ms. Joyce LaViscount has joined the Company’s leadership team as Chief ... Read More

        All Press